Efficacy of intermittently scanned continuous glucose monitoring in the prevention of recurrent severe hypoglycemia.
People with diabetes experiencing hypoglycemia are at increased risk of recurrence because of attenuated autonomic warning. We assessed the efficacy of intermittently scanned continuous glucose monitoring (isCGM; FreeStyle LibreTM, Abbott) compared with usual care (self-monitoring of blood glucose; SMBG) in reducing this risk in type 1 and insulin-treated type 2 diabetes. Insulin-treated adults with diabetes and an episode of clinically significant biochemical hypoglycemia (blood glucose (BG) <3.0 mmol/L) or symptomatic hypoglycaemia and BG <4.0 mmol/L were randomized to six months of isCGM (intensive group) or SMBG (control group) against a background of usual care. The primary outcome was hypoglycemia requiring second party assistance for recovery. Pre-specified secondary outcomes included other hypoglycemic episodes (self-reported, and BG <3.0, 3.0-3.9, <4.0 mmol/L) and change in HbA1c at 24 weeks. Of 59 participants (mean age 53.6 years, 44.1% males, median HbA1c 61.8 mmol/mol or 7.8%), 30 were allocated to isCGM and 29 to SMBG. The incidence of severe hypoglycemia was not significantly different between the two groups (incident rate ratio (95% CI) 1.49 (0.46-5.56), P=0.47). The incidence of other recorded hypoglycemic episodes in the intervention group was double that in the control group (P<0.001). There was no difference in the change in HbA1c between the two groups (P=0.74). There were seven serious adverse events and none were considered related to the intervention. Although isCGM is safe, it does not appear to have a role in preventing recurrent severe hypoglycemia in at-risk individuals with diabetes.